Docket No.: PF-0629 USN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on December 13, 2001.

By: Printed: Lyza Finuliar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Hillman et al.

Title:

GTPASE ASSOCIATED PROTEINS

Serial No.:

09/856,679

Filed:

To Be Assigned

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Box PCT

Commissioner for Patents Washington, D.C. 20231

SUBMISSION UNDER 37 CFR §1.821- 1.825 SEQUENCE LISTING

Sir:

In accordance with the requirements of 37 CFR §1.821- 1.825, Applicants hereby submit one (1) diskette containing the computer-readable information for the "Sequence Listing" of the above-identified application. The diskette complies with the requirements of 37 CFR §1.824 and is IBM PC compatible using a UNIX operating system with PERL Program.

The content of the "Sequence Listing" paper copy, as originally submitted with the above-identified application, is identical to the computer readable copy, submitted herewith, as required under 37 CFR § 1.821(f).

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 13 Do Combar 2001

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650)845-4639

3160 Porter Drive Palo Alto, California, 94304 Tel. No. 650-855-0555 Fax. No. 650-849-8886

88980 1 09/856,679

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY, DOCKET NO.			
09/856679	HILIMAN	J		PF-0629 USN	
		INTERNATIONAL AP		PPLICATION NO.	
DIANA HAMLET COX INCYTE GENOMICS		"	PCT/US99/28013		
3160 PORTER DRIVE PALO ALTO, CA 94304		I.A. FILIN	G DATE	PRIORITY DATE	
FALO ALTO, CA 54304		23 NO	V 99	23 NOV 98	
		DATE	MAILED: 1	5 AUG 2001	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
APPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
amendment directing its entry into the specification.
A statement that the contents of the paper or compact disc and the computer readable form
are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE

SHELBY VIGIL, PARALEGAL

Telephone: 703-305-6114

FORM PCT/DO/EO/920 (March 2001)

(703) 308-4216, for Rules interpretation,(703) 308-4212, for CRF submission help,(703) 287-0200, for Patentin software help.

CALL:

Docket No.: PF-0629 USN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope honer for Patents, Box Sequence, Washington, D.C. 20231 on December 13, 2001.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title:

GTPASE ASSOCIATED PROTEINS

Serial No.:

09/856,679

Filing Date:

To Be Assigned

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Box PCT

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy attached) mailed by the United States Patent and Trademark Office on August 15, 2001, the period of time for response has been extended until December 15, 2001, by the accompanying Petition and fee. Applicants submit the following documents to complete the filing for the above-identified patent application:

- 1. Submission Under 37 CFR §1.821-1.825 Sequence Listing (1 page); and
- One (1) CRF Diskette containing the computer-readable information for the Sequence 2. Listing.

If the USPTO determines that any additional fees are due, the Commissioner is hereby authorized to debit or credit (respectively) Deposit Account No. 09-0108.

1 09/856,679 88975

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 13 Documber 2001

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 849-8886

88975 2 09/856,679